Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

@article{LoRusso2008PhaseIC,
  title={Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors},
  author={Patricia M. LoRusso and Shirish M. Gadgeel and Antoinette Wozniak and Alan J. Barge and Helen K. Jones and Zachary S Delproposto and Pamela Deluca and Jeffrey L. Evelhoch and Scott A. Boerner and C. C. Wheeler},
  journal={Investigational New Drugs},
  year={2008},
  volume={26},
  pages={159-167}
}
Background ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis. This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126. Methods Adult patients with solid tumors refractory to existing treatments received a 10-min, single-dose intravenous infusion of ZD6126 every 14 or 21 days. Subsequent dose escalation was performed, based on the… CONTINUE READING
25 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Bevacizumab plus 166 Invest New Drugs (2008) 26:159–167 irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

  • H Hurwitz, L Fehrenbacher, +12 authors F Kabbinavar
  • N Engl J Med
  • 2004
1 Excerpt

Similar Papers

Loading similar papers…